• The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
  • This web site is a service of Prostate Cancer International.

    pcai_cmyk

  • Other PCI web sites

  • The "New" Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services.

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The "New" Prostate Cancer InfoLink is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

    • Perspective Confidentiality Disclosure Reliability Courtesy

Radiotherapy + ADT following radical prostatectomy

A Canadian group has just added a little more to our knowledge about the role of neoadjuvant hormone therapy in association with radiotherapy after first-line radical prostatectomy (RP).

Pai et al. have reported data from a  retrospective analysis performed on 175 patients with clinically localized prostate cancer who were first treated with RP and who who subsequently received radiotherapy (dose range 50 Gy-68 Gy, which is still a slightly low dose range compared to the higher ranges observed normally today).

Twenty-two patients received adjuvant radiotherapy (ART), 57 received neoadjuvant androgen deprivation therapy (NADT) + ART, 15 received salvage radiation therapy (SRT), and 81 received NADT + SRT. Outcome was assessed by biochemical disease-free survival , prostate cancer-specific survival, and overall survival.

Biochemical disease-free survival at 5 years was observed in:

  • 67 percent of ART patients
  • 80 percent of NADT + ART patients
  • 27 percent of SRT patients
  • 62 percent of NADT + SRT patients

which would seem to suggest an overall benefit for patients who received NADT  + ART compared to other options. However, it turned out that on multivariate analysis the only three independent predictive factors of improved biochemical disease-free survival were a PSA level ≤ 0.2 ng/ml before radiotherapy, a low Gleason score, and positive surgical margins.  The patient’s age and his Gleason score were independent predictors of overall survival.

The authors conclude that:

  • The pre-radiotherapy PSA level is an important predictor of outcome.
  • NADT appears to benefit patients who presented with a pre-radiotherapy PSA level > 0.2 ng/ml, particularly for patients receiving SRT.
  • NADT can be considered for patients receiving radiotherapy after RP who present with a high pre-radiotherapy PSA level, but may not be necessary for patients with a low PSA level.

Leave a Reply